Combining Mutational Signatures, Clonal Fitness, and Drug Affinity to Define Drug-Specific Resistance Mutations in Cancer

about

Combining Mutational Signatures, Clonal Fitness, and Drug Affinity to Define Drug-Specific Resistance Mutations in Cancer

Item

http://www.wikidata.org/entity/Q59125278

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в листопаді 2018

@uk

name

Combining Mutational Signature ...... Resistance Mutations in Cancer

@en

Combining Mutational Signature ...... Resistance Mutations in Cancer

@nl

type

Item

label

Combining Mutational Signature ...... Resistance Mutations in Cancer

@en

Combining Mutational Signature ...... Resistance Mutations in Cancer

@nl

prefLabel

Combining Mutational Signature ...... Resistance Mutations in Cancer

@en

Combining Mutational Signature ...... Resistance Mutations in Cancer

@nl

P1476

Combining Mutational Signature ...... Resistance Mutations in Cancer

@en

P2093

Julian Blagg

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha

Specificity of linear motifs that bind to a common mitogen-activated protein kinase docking groove

The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor

Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia

Structure of a c-kit product complex reveals the basis for kinase transactivation

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients

Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain

P304

1359-1371.e2

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CHEMBIOL.2018.07.013

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Teresa Kaserer

P577

2018-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30146241

http://www.w3.org/2001/XMLSchema#string

P921

drug discovery

molecular medicine

molecular biology

P932

6242700

http://www.w3.org/2001/XMLSchema#string